All articles by Staff Writer
Staff Writer
SEKISUI Diagnostics and Aptitude Partner to Provide Metrix COVID-19 Tests to the Point-of-Care and Home Test Markets
SEKISUI Diagnostics, a global medical diagnostics manufacturer, has formalized an exclusive distribution agreement with Aptitude Medical Systems (Aptitude™), an innovative developer of decentralized molecular diagnostics, to sell the Aptitude MetrixTM COVID-19 Test in the U.S. The Metrix test is currently the only EUA approved, molecular test which can be used with both swab and saliva samples and can performed by healthcare professionals or at home by consumers.
Oxford Nanopore and Guy’s and St Thomas’ NHS Foundation Trust showcase a world-first collaboration in infectious disease
Successful pilot programme results in government funding to embed rapid pathogen genomic sequencing capability into clinical research settings to improve patient outcomes and biosecurity.
PulseAI’s Groundbreaking AI Algorithm Enhances Consumer ECG Diagnostics
Innovative AI Application Improves Cardiac Monitoring and Diagnostic Accuracy
Bruker Announces Acquisition of Tornado Spectral Systems to Expand Its Biopharma Process Analytical Technology (PAT) Product Portfolio
Bruker (Nasdaq: BRKR) today announced the acquisition of Tornado Spectral Systems Inc., a Canadian company specializing in process Raman instruments, primarily used in pharma and biotech quality control applications. Tornado, with over a decade of experience in innovative and industry-proven Raman solutions, will enhance Bruker’s biopharma PAT portfolio with its well-established products. Financial details were not disclosed.
bioMérieux acquires LUMED to reinforce its software portfolio in the fight against antimicrobial resistance
bioMérieux, a world leader in the field of in vitro diagnostics, announces the acquisition of LUMED, a software company that has developed a clinical decision support system to help hospitals optimize antimicrobial prescriptions and monitor healthcare-associated infections.
QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. Food and Drug Administration (FDA) clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu for its integrated PCR-based clinical molecular testing systems NeuMoDx 96 and 288 in the United States.
Thermo Fisher Scientific Launches PangenomiX Array to Support Population-Scale Disease Studies and Pharmacogenomics Research
Most comprehensive and ethnically diverse genomic coverage on a high throughput microarray delivers multi-disease and pharmacogenomic research analysis across global populations
QIAGEN expands business in Middle East with new regional headquarters and major projects
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant expansion of its business in the Middle East region, which includes three major developments:
Roche enters into a definitive agreement to acquire LumiraDx’s Point of Care technology combining multiple diagnostic modalities on a single platform
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive agreement to acquire select parts of the LumiraDx group (NASDAQ GS: LMDX) related to LumiraDx’s innovative Point of Care technology. Following closing of the transaction, which is expected by mid-2024, the acquired entities will be fully integrated into Roche Diagnostics.
Q-linea installs first ASTars in the United States pending market approval
Q-linea AB (publ) (OMX:QLINEA) today announces that the company has installed its first two systems in the United States, offering selected sites access to ASTar, pending marketing authorization and commercial launch.